DSGN
Design Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$761.65M
P/E Ratio
—
EPS
$-1.22
Beta
1.58
52W High
$12.84
52W Low
$3.10
50-Day MA
$10.60
200-Day MA
$7.73
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Design Therapeutics Inc
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad, California.
Fundamentals
| Revenue (TTM) | 33,000 |
| Gross Profit (TTM) | $-59.13M |
| EBITDA | $-78.44M |
| Operating Margin | 0.00% |
| Return on Equity | -30.70% |
| Return on Assets | -20.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.52 |
| Price-to-Book | 3.53 |
| Price-to-Sales (TTM) | 29402.82 |
| EV/Revenue | 17818.79 |
| EV/EBITDA | -0.84 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $61.67M |
| Float | $29.20M |
| % Insiders | 33.35% |
| % Institutions | 62.32% |
Historical Volatility
HV 10-Day
64.83%
HV 20-Day
62.55%
HV 30-Day
55.96%
HV 60-Day
53.22%
HV Rank
11.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($14.67 target)
2
Strong Buy3
BuyData last updated: 4/14/2026